Biopsy follow-up of prostate-specific antigen tests (Q36567436)

15 August 2017

Biopsy follow-up of prostate-specific antigen tests (English)

1 reference

15 August 2017

2

Diana S M Buist

1 reference

15 August 2017

Steven B Zeliadt

1

1 reference

15 August 2017

Robert J Reid

3

1 reference

15 August 2017

David C Grossman

4

1 reference

15 August 2017

Jian Ma

5

1 reference

15 August 2017

Ruth Etzioni

6

1 reference

15 August 2017

1 January 2012

1 reference

American Journal of Preventive Medicine

15 August 2017

1 reference

15 August 2017

42

1 reference

15 August 2017

1

1 reference

15 August 2017

37-43

1 reference

What happens after an elevated PSA test: the experience of 13,591 veterans

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556898

NCCN clinical practice guidelines in oncology: prostate cancer early detection

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556898

Prostate specific antigen best practice statement: 2009 update.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556898

Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556898

Timely follow-up of positive fecal occult blood tests strategies associated with improvement

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556898

Patterns in prostate-specific antigen test use and digital rectal examinations in the Behavioral Risk Factor Surveillance System, 2002-2006.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556898

Screening and prostate-cancer mortality in a randomized European study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556898

Mortality results from a randomized prostate-cancer screening trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556898

Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556898

Improvement in the diagnostic evaluation of a positive fecal occult blood test in an integrated health care organization

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556898

Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556898

Prostate-specific antigen levels in the United States: implications of various definitions for abnormal

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556898

Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556898

Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556898

Risk adjustment using automated ambulatory pharmacy data: the RxRisk model

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556898

What's the relative risk? A method to directly estimate risk ratios in cohort studies of common outcomes

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556898

Practice trends in the management of prostate disease by family practice physicians and general internists: an internet-based survey

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556898

Prostate-specific antigen testing in black and white men: an analysis of medicare claims from 1991-1998.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556898

Prostate-specific antigen for prostate cancer screening. Do physician characteristics affect its use?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556898

Prostate-specific antigen testing practices and outcomes.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556898

Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556898

Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556898

PSA screening: a public health dilemma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556898

Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Data from the American Cancer Society National Prostate Cancer Detection Project

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556898

Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556898

Continuity of care and cancer screening among health plan enrollees

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556898

Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556898

Estimating the Relative Risk in Cohort Studies and Clinical Trials of Common Outcomes

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556898

Long-Term Prediction of Prostate Cancer: Prostate-Specific Antigen (PSA) Velocity Is Predictive but Does Not Improve the Predictive Accuracy of a Single PSA Measurement 15 Years or More Before Cancer Diagnosis in a Large, Representative, Unscreened P

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3556898

Lowering PSA cutoffs to enhance detection of curable prostate cancer

4 December 2018

1 reference

12 December 2020

Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate

1 reference

12 December 2020

Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease

1 reference

12 December 2020

Clinical practice and new technology: prostate-specific antigen (PSA)

1 reference

12 December 2020

A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer

1 reference

12 December 2020

Early stage prostate cancer--do we have a problem with over-detection, overtreatment or both?

1 reference

12 December 2020

Does PSA velocity predict prostate cancer in pre-screened populations?

1 reference

12 December 2020

Methods of calculating prostate-specific antigen velocity

1 reference

12 December 2020

It's Time to Abandon an Upper Limit of Normal for Prostate Specific Antigen: Assessing the Risk of Prostate Cancer

1 reference

12 December 2020

10.1016/J.AMEPRE.2011.08.024

Identifiers

DOI

1 reference

15 August 2017

1 reference

15 August 2017

1 reference